Cardiol Therapeutics Inc. (CRDL)


+0.01 (+0.70%)
Symbol CRDL
Price $0.8904
Beta 0.899
Volume Avg. 0.18M
Market Cap 57.544M
Shares () -
52 Week Range 0.45-1.235
1y Target Est -
DCF Unlevered CRDL DCF ->
DCF Levered CRDL LDCF ->
ROE -61.58% Strong Sell
ROA -63.70% Strong Sell
Operating Margin -
Debt / Equity 0.12% Neutral
P/E -2.78 Sell
P/B 1.99 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest CRDL news

Mr. David G. Elsley MBA
Drug Manufacturers—Specialty & Generic
NASDAQ Capital Market

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.